Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.

Wong, T H; Sinclair, S; Smith, B; Fraser, C; Morton, C A

Wong, T H; Sinclair, S; Smith, B; Fraser, C; Morton, C A.

Affiliation

Wong TH; Department of Dermatology, Stirling Community Hospital, Livilands Gate, Stirling, FK8 2AU, UK.
Sinclair S; Department of Dermatology, Stirling Community Hospital, Livilands Gate, Stirling, FK8 2AU, UK.
Smith B; Department of Dermatology, Stirling Community Hospital, Livilands Gate, Stirling, FK8 2AU, UK.
Fraser C; Department of Dermatology, Stirling Community Hospital, Livilands Gate, Stirling, FK8 2AU, UK.
Morton CA; Department of Dermatology, Stirling Community Hospital, Livilands Gate, Stirling, FK8 2AU, UK.

Clin Exp Dermatol ; 42(6): 675-676, 2017 Aug.

Article in En | MEDLINE | ID: mdl-28621002

Subject(s)

Anti-Inflammatory Agents, Non-Steroidal/therapeutic use; Phosphodiesterase 4 Inhibitors/therapeutic use; Psoriasis/drug therapy; Thalidomide/analogs & derivatives; Adult; Aged; Female; Humans; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Thalidomide/therapeutic use; Young Adult

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Thalidomide / Anti-Inflammatory Agents, Non-Steroidal / Phosphodiesterase 4 Inhibitors Type of study: Observational_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Exp Dermatol Year: 2017 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google